SALT LAKE CITY, July 29, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it is hosting a booth at the Association for Diagnostics & Laboratory Medicine (ADLM) annual meeting and expo held July 28-August 1, 2024, in Chicago, IL.

Co-Dx will also be holding a special company presentation to discuss the role of its new at-home and point-of-care Co-Dx™ PCR platform* in closing the global diagnostics gap for an array of potential indications, including tuberculosis (TB). The platform's first FDA 510(k) application, for a COVID-19 test, was submitted in mid-June. Other tests in the pipeline are expected to meet the diverse needs of a global market.

The presentation will take place in Room S102D at 2:00 PM local time on Tuesday, July 30, and will include Co-Dx CEO Dwight Egan and Co-Dx Executive VP of Business Development Joseph Featherstone addressing how the company is taking an advanced position in the worldwide initiative to end TB by 2030.

In addition to the Company's current and planned pipeline of testing products, both for the new platform and for its existing customer base of distributors and clinical laboratories around the world, the Co-Dx booth will showcase the Co-Dx PCR Pro™ instrument, which is currently under FDA review and is not available for sale. The Company will also be presenting a scientific poster, #B-192, at 1:30-2:30 on July 31^st.

Attendees interested in learning more are invited to visit the Company at Booth 2879. Information about the ADLM conference may be found here.

*The Co-Dx PCR platform (including the PCR Home™, PCR Pro™, mobile app, and all associated tests) is subject to review by the FDA and/or other regulatory bodies and is not available for sale. The Co-Dx PCR Pro instrument and Co-Dx COVID-19 Test are currently under review by the FDA and are not available for sale.

About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform and to locate genetic markers for use in applications other than infectious disease.

Forward-Looking Statements:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA) that are subject to a number of risks and uncertainties. Forward-looking statements can be identified by words such as "believes," "expects," "estimates," "intends," "may," "plans," "will" and similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. Forward-looking statements in this release include statements regarding the role of our new at-home and point-of-care Co-Dx™ PCR platform in closing the global diagnostics gap for an array of indications.  Actual results may differ materially from those contemplated or anticipated by such forward-looking statements. Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. There can be no assurance that any of the anticipated results will occur on a timely basis or at all due to certain risks and uncertainties, a discussion of which can be found in our Risk Factors disclosure in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission (SEC) on March 14, 2024, and in our other filings with the SEC. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.

SOURCE Co-Diagnostics